NeuroKaire Featured in 360Dx for U.S. Launch of BrightKaire Depression Test
360Dx spotlights NeuroKaire’s rebrand and U.S. launch of its groundbreaking BrightKaire test — a blood-based test helping clinicians personalize treatment for depression.
NeuroKaire was recently featured in 360Dx, a leading publication in molecular diagnostics, for its entrance into the U.S. precision psychiatry market. The article highlights NeuroKaire’s rebrand, recent CLIA certification, and the clinical introduction of BrightKaire, a first-of-its-kind blood test for depression care.
BrightKaire uniquely combines pharmacogenetics with functional data from patient-derived neurons, helping clinicians identify the most effective antidepressant for each individual. The feature explores how this innovation aims to replace trial-and-error with personalized, biology-based guidance — representing a major advancement in mental health diagnostics and treatment selection.
Full Text Here: https://www.360dx.com/molecular-diagnostics/rebrand-and-us-launch-depression-test-neurokaire-enters-precision-psychiatry
Note: Access to the full article may require a subscription to 360Dx.
Contact Us
78 John Miller Way,
Kearny, NJ 07032, USA
Yigal Alon Street 126
Tel Aviv-Yafo, Israel